NO20034996D0 - Nye arylsusfonamidforbindelser for behandlingen av fedme, type II diabetesog CNS-forstyrrelser - Google Patents

Nye arylsusfonamidforbindelser for behandlingen av fedme, type II diabetesog CNS-forstyrrelser

Info

Publication number
NO20034996D0
NO20034996D0 NO20034996A NO20034996A NO20034996D0 NO 20034996 D0 NO20034996 D0 NO 20034996D0 NO 20034996 A NO20034996 A NO 20034996A NO 20034996 A NO20034996 A NO 20034996A NO 20034996 D0 NO20034996 D0 NO 20034996D0
Authority
NO
Norway
Prior art keywords
arylsus
phonamide
obesity
diabetes
compounds
Prior art date
Application number
NO20034996A
Other languages
English (en)
Other versions
NO326690B1 (no
Inventor
Patrizia Caldirola
Ulf Bremberg
Annika Jenmalm Jensen
Gary Johansson
Andrew Mott
Lori Sutin
Jan Tejbrant
Original Assignee
Biovitrum Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0101660A external-priority patent/SE0101660D0/xx
Priority claimed from SE0101659A external-priority patent/SE0101659D0/xx
Priority claimed from SE0101958A external-priority patent/SE0101958D0/xx
Application filed by Biovitrum Ab filed Critical Biovitrum Ab
Publication of NO20034996D0 publication Critical patent/NO20034996D0/no
Publication of NO326690B1 publication Critical patent/NO326690B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20034996A 2001-05-11 2003-11-10 Nye arylsusfonamidforbindelser for behandlingen av fedme og type II diabetes, fremgangsmåte for fremstilling derav, samt farmasøytiske formuleringer som inneholder slike NO326690B1 (no)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
SE0101660A SE0101660D0 (sv) 2001-05-11 2001-05-11 New compounds
SE0101659A SE0101659D0 (sv) 2001-05-11 2001-05-11 New compounds
US29410201P 2001-05-29 2001-05-29
US29413201P 2001-05-29 2001-05-29
SE0101958A SE0101958D0 (sv) 2001-06-05 2001-06-05 New compounds
PCT/SE2002/000906 WO2002092585A1 (en) 2001-05-11 2002-05-08 Novel, arylsusfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders

Publications (2)

Publication Number Publication Date
NO20034996D0 true NO20034996D0 (no) 2003-11-10
NO326690B1 NO326690B1 (no) 2009-01-26

Family

ID=27532724

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20034996A NO326690B1 (no) 2001-05-11 2003-11-10 Nye arylsusfonamidforbindelser for behandlingen av fedme og type II diabetes, fremgangsmåte for fremstilling derav, samt farmasøytiske formuleringer som inneholder slike

Country Status (16)

Country Link
US (4) US7173035B2 (no)
EP (1) EP1406884A1 (no)
JP (2) JP4597480B2 (no)
KR (1) KR20090092832A (no)
CN (1) CN1329382C (no)
AU (1) AU2002303061B2 (no)
BR (1) BR0209558A (no)
CA (1) CA2443724C (no)
EA (1) EA009647B1 (no)
HK (1) HK1068335A1 (no)
IL (3) IL158593A0 (no)
MX (1) MXPA03010232A (no)
NO (1) NO326690B1 (no)
NZ (1) NZ528450A (no)
PL (1) PL366619A1 (no)
WO (1) WO2002092585A1 (no)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7718650B2 (en) * 2001-05-11 2010-05-18 Biovitrum Ab Aryl sulfonamide compounds for treating obesity
CA2443724C (en) * 2001-05-11 2009-11-03 Patrizia Caldirola Novel, arylsusfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders
US20020197228A1 (en) * 2001-05-29 2002-12-26 Lasala William Kater Skin care kit
NZ529032A (en) 2001-06-11 2007-04-27 Biovitrum Ab Substituted sulfonamide compounds, process for their use as medicament for the treatment of CNS disorders, obesity and type II diabetes
US7456184B2 (en) 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
US7718802B2 (en) 2001-08-10 2010-05-18 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
CA2462200A1 (en) 2001-08-10 2003-02-20 Palatin Technologies, Inc. Peptidomimetics of biologically active metallopeptides
US7732451B2 (en) 2001-08-10 2010-06-08 Palatin Technologies, Inc. Naphthalene-containing melanocortin receptor-specific small molecule
US7354923B2 (en) * 2001-08-10 2008-04-08 Palatin Technologies, Inc. Piperazine melanocortin-specific compounds
US7655658B2 (en) 2001-08-10 2010-02-02 Palatin Technologies, Inc. Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
WO2003072063A2 (en) * 2002-02-28 2003-09-04 Temple University - Of The Commonwealth System Of Higher Education Amino-substituted sulfonanilides and derivatives thereof for treating proliferative disorders
JP4754821B2 (ja) 2002-06-20 2011-08-24 プロキシマゲン・リミテッド 肥満症、ｉｉ型糖尿病およびｃｎｓ障害の治療に有用な新規化合物
AU2003243091A1 (en) * 2002-06-20 2004-01-06 Biovitrum Ab (Publ) New compounds useful for the treatment of obesity, type ii diabetes and cns disorders
GB0224830D0 (en) 2002-10-24 2002-12-04 Sterix Ltd Compound
SE0203754D0 (sv) * 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
SE0203753D0 (sv) 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
US7319111B2 (en) * 2003-02-20 2008-01-15 Encysive Pharmaceuticals, Inc. Phenylenediamine Urotensin-II receptor antagonists and CCR-9 antagonists
US7727990B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine and keto-piperazine compounds
US7727991B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Substituted melanocortin receptor-specific single acyl piperazine compounds
US7968548B2 (en) 2003-05-01 2011-06-28 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine compounds with diamine groups
CN1809545A (zh) * 2003-06-20 2006-07-26 艾尼纳制药公司 N－苯基－哌嗪衍生物和预防或者治疗5HT2c受体相关疾病的方法
US20050201965A1 (en) * 2004-03-11 2005-09-15 The Procter & Gamble Company Personal cleansing compositions
US7709484B1 (en) 2004-04-19 2010-05-04 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
WO2005113513A2 (en) 2004-05-12 2005-12-01 Chemocentryx Aryl sulfonamides
CA2584502A1 (en) 2004-06-24 2006-01-05 Incyte Corporation 2-methylpropanamides and their use as pharmaceuticals
EP1758882A4 (en) * 2004-06-24 2008-01-23 Incyte Corp AMID COMPOUNDS AND THEIR USE AS MEDICAMENTS
US7582673B2 (en) * 2004-10-21 2009-09-01 High Point Pharmaceuticals, Llc Bissulfonamide compounds as agonists of GalR1, compositions, and methods of use
CN101084206A (zh) * 2004-12-13 2007-12-05 艾尼纳制药公司 作为5ht2c受体调节剂以治疗与其相关病症的n－联芳基和n－芳基杂芳基2－经取代哌嗪衍生物
EP1695971A1 (en) * 2004-12-30 2006-08-30 Laboratorios Del Dr. Esteve, S.A. Substituted phenyl-piperazine compounds, their preparation and use in medicaments
EP1676842A1 (en) * 2004-12-30 2006-07-05 Laboratorios Del Dr. Esteve, S.A. Nitro-substituted phenyl-piperazine compounds, their preparation and use in medicaments
NZ556761A (en) * 2005-01-25 2011-04-29 Galenea Corp Substituted arylamine compounds and their use as 5-HT6 modulators
JP2009530231A (ja) * 2006-01-20 2009-08-27 スミスクライン ビーチャム コーポレーション 代謝及び神経系の疾患の治療におけるスルホンアミド誘導体の使用
US8642642B2 (en) * 2006-04-19 2014-02-04 Abbott Laboratories Heterocyclic arylsulphones suitable for treating disorders that respond to modulation of the serotonin 5HT6 receptor
US7834017B2 (en) 2006-08-11 2010-11-16 Palatin Technologies, Inc. Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents
WO2009137597A1 (en) * 2008-05-06 2009-11-12 The Trustees Of Columbia University In The City Of New York COMPOUNDS THAT INHIBIT PRODUCTION OF sAPPβ AND Aβ AND USES THEREOF
WO2010051064A1 (en) 2008-10-30 2010-05-06 The Trustees Of Columbia University In The City Of New York COMPOUNDS THAT INHIBIT NFκB ACTIVITY
WO2010125136A1 (en) * 2009-04-30 2010-11-04 Abbott Gmbh & Co. Kg Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor
US8343959B2 (en) 2009-04-30 2013-01-01 Abbott Gmbh & Co. Kg N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor
CA2759491A1 (en) 2009-04-30 2010-11-04 Abbott Gmbh & Co. Kg. Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor
SG175187A1 (en) 2009-04-30 2011-11-28 Abbott Gmbh & Co Kg N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor
CA2803118C (en) 2010-07-09 2015-11-03 Pfizer Limited Sulfonamide derivatives as nav 1.7 inhibitors
WO2012059431A1 (en) 2010-11-01 2012-05-10 Abbott Gmbh & Co. Kg Benzenesulfonyl or sulfonamide compounds suitable for treating disorders that respond to the modulation of the serotonin 5-ht6 receptor
WO2012059432A1 (en) 2010-11-01 2012-05-10 Abbott Gmbh & Co. Kg N-phenyl-(homo)piperazinyl-benzenesulfonyl or benzenesulfonamide compounds suitable for treating disorders that respond to the modulation of the 5-ht6 receptor
TWI754702B (zh) * 2016-12-28 2022-02-11 德商Ｕｃｂ製藥有限公司 （氮雜）吲哚－和苯並呋喃－３－磺醯胺類

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2033597A5 (en) * 1969-02-28 1970-12-04 Ugine Kuhlmann Green phthalocyanine metal dyes
DE2239846A1 (de) * 1972-08-12 1974-02-14 Hoechst Ag Basisch substituierte benzol-1,3disulfonamide und verfahren zu ihrer herstellung
DE2334562A1 (de) * 1973-07-07 1975-01-30 Hoechst Ag Basisch substituierte benzol-1,3-disulfonamide und verfahren zu ihrer herstellung
NL7310889A (no) * 1972-08-12 1974-02-14
DE2459394A1 (de) * 1974-12-16 1976-06-24 Hoechst Ag Basisch substituierte benzol-1,3- disulfonamide und verfahren zu ihrer herstellung
CA1331757C (en) * 1988-02-29 1994-08-30 Janssen Pharmaceutica Naamloze Vennootschap 5-lipoxygenase inhibiting 4-(4-phenyl-1-piperazinyl)phenols
DE19541146A1 (de) * 1995-10-25 1997-04-30 Schering Ag Imidazolderivate und deren Verwendung als Stickstoffmonoxid-Synthase-Inhibitoren
US5939451A (en) * 1996-06-28 1999-08-17 Hoffmann-La Roche Inc. Use of sulfonamides
CA2263167C (en) * 1996-08-15 2006-02-14 Schering Corporation Ether muscarinic antagonists
DZ2376A1 (fr) * 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
CN1087294C (zh) * 1997-07-11 2002-07-10 史密丝克莱恩比彻姆有限公司 新化合物
GB9801392D0 (en) * 1998-01-22 1998-03-18 Smithkline Beecham Plc Novel compounds
AU759255B2 (en) * 1998-01-29 2003-04-10 Amgen, Inc. PPAR-gamma modulators
GB9803411D0 (en) * 1998-02-18 1998-04-15 Smithkline Beecham Plc Novel compounds
US6943159B1 (en) * 1998-02-18 2005-09-13 Neurosearch A/S Compounds and their use as positive AMPA receptor modulators
KR20010070997A (ko) * 1998-07-20 2001-07-28 플레믹 크리스티안 비페닐 유도체
GB9818916D0 (en) * 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
GB9818914D0 (en) * 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
DE19941559A1 (de) * 1999-09-01 2001-03-15 Aventis Pharma Gmbh Verwendung von Bissulfonamiden zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Hyperlipidömie
AU774071B2 (en) * 1999-09-01 2004-06-17 Sanofi-Aventis Deutschland Gmbh Sulfonyl carboxamide derivatives, method for their production and their use as medicaments
US6399617B1 (en) * 2000-07-21 2002-06-04 Biovitrum Ab Use
CA2443724C (en) * 2001-05-11 2009-11-03 Patrizia Caldirola Novel, arylsusfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders

Also Published As

Publication number Publication date
KR20090092832A (ko) 2009-09-01
JP2004534755A (ja) 2004-11-18
EP1406884A1 (en) 2004-04-14
US20030149020A1 (en) 2003-08-07
US6969710B2 (en) 2005-11-29
JP2011016801A (ja) 2011-01-27
US20060009446A1 (en) 2006-01-12
US7173035B2 (en) 2007-02-06
JP4597480B2 (ja) 2010-12-15
WO2002092585A1 (en) 2002-11-21
CN1329382C (zh) 2007-08-01
BR0209558A (pt) 2004-04-20
MXPA03010232A (es) 2004-03-16
AU2002303061B2 (en) 2009-01-29
PL366619A1 (en) 2005-02-07
CA2443724C (en) 2009-11-03
EA009647B1 (ru) 2008-02-28
US7319097B2 (en) 2008-01-15
US7566715B2 (en) 2009-07-28
NZ528450A (en) 2006-02-24
US20050288275A1 (en) 2005-12-29
IL158593A (en) 2010-12-30
IL158593A0 (en) 2004-05-12
CN1531531A (zh) 2004-09-22
US20030149019A1 (en) 2003-08-07
IL194950A0 (en) 2011-08-01
HK1068335A1 (en) 2005-04-29
CA2443724A1 (en) 2002-11-21
NO326690B1 (no) 2009-01-26
EA200301232A1 (ru) 2004-04-29

Similar Documents

Publication Publication Date Title
NO20034996D0 (no) Nye arylsusfonamidforbindelser for behandlingen av fedme, type II diabetesog CNS-forstyrrelser
HK1066790A1 (en) Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes
IL165051A0 (en) New compounds useful for the treatment of obesity,type II diabetes and cns disorders
NO20041452L (no) 17-beta-hydroksysteroid-dehydrogenase type 3-inhibitorer for behandling av androgenavhengige sykdommer.
IS7099A (is) Efnasambönd til að meðhöndla bólgutruflanir
NO20041216L (no) Imidazol-4-karboksamidderivater, fremstilling og anvendelse derav for behandling av overvekt
NO20014047D0 (no) Monoamin reopptaksinhibitorer for behandling av CNS forstyrrelser
NO20043237L (no) Dihydrobenzodiazepin-2-onderivater for behandling av neurologiske forstyrrelser
NO20081016L (no) Nye 1-aryl-3-azabicyklo(3.1.0)heksaner, fremstilling og bruk for å behandle nevropsykiatriske lidelser
NO20053211D0 (no) Forbindelser for behandling av metabolske forstyrrelser.
NO20052223D0 (no) Tiazolforbindelser for behandling av neurodegenerative forstyrrelser
NO20053041D0 (no) Behandling av diabetes.
AU2003299791A1 (en) Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
MXPA03007960A (es) Compuestos y metodos para el tratamiento de desordenes urogenitales.
EP1363625A4 (en) COMBINATIONS OF DRUGS (eg, BENZIMIDAZOLE AND PENTAMIDINE) IN THE TREATMENT OF NEOPLASTIC DISORDERS
AU2003281978A1 (en) 2,5-diketopiperazines for the treatment of obesity
IL158631A0 (en) 4-(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
NO20055098D0 (no) Anvendelse av 10-hydroksy-10,11-dihydrokarbamazepinderivater for behandling av affektive forstyrrelser
EP1625207A4 (en) COMPOUNDS FOR THE TREATMENT OF INFLAMMATION, DIABETES AND RELATED DISORDERS
AU2002258428A1 (en) Methods for the treatment of metabolic disorders, including obesity and diabetes
DK1491212T3 (da) Middel til behandling af søvnforstyrrelser
NO20045554L (no) Fremgangsmate for behandling av diabetes
NO20033803D0 (no) Karbamat for behandling av bevegelseslidelser
IS6077A (is) Efnasambönd og aðferðir til meðhöndlunar á asma, ofnæmi og bólgutruflunum
NO20033417L (no) Anvendelse av CD23-antagonister for behandling av neoplastiske forstyrrelser

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees